Drugs / RGT-419B
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06299124 | Apr 2023 → Jul 2025 overdue | breast cancer | Regor Pharmaceuticals Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05304962 | Mar 2022 → Sep 2026 expected | breast cancer | Regor Pharmaceuticals Inc. | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07100106 | Oct 2025 → Aug 2028 expected | breast cancer | Genentech, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RGT-419B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06299124 ↗ |
| Known as | GDC-4198 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07100106 ↗ |
| Route | Oral | “administered orally” NCT05304962 ↗ |